In the United States, approximately 250,000 people have been diagnosed with a primary immunodeficiency (PI) disorder, and these patients have increased vulnerability to severe infections as well as lifelong impairment. Despite the severity of this disorder, however, there are significant disparities in diagnosis, treatment, and outcomes for patients diagnosed with PI who are from racial and ethnic underserved populations, as well as those of lower socioeconomic status.
This CME Outfitters Webcast will focus on addressing these persistent health disparities. Expert faculty will engage the audience in the development of improved skills in identifying the signs and symptoms of PI to reduce diagnostic delays, emphasize the importance of implementing consistent, guideline-directed treatment plans for all patients, and advise on the importance of effective patient-clinician communication and education.
At the end of this CME/CE activity, participants should be able to:
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Physicians, nurse practitioners, PAs, infusion nurses, pharmacists, or other clinicians in primary care, as well as any clinician who manages or treats patients with PI.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Patel reports the following financial relationships: Advisory Board: CSL Behring; Horizon Therapeutics; and Takeda Pharmaceuticals U.S.A., Inc. Consultant: Horizon Therapeutics. Grants: CSL Behring. Research Support: CSL Behring and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Azar reports the following financial relationships: Advisory Board: Grifols and Opinose. Consultant: Argenx and Takeda Pharmaceuticals U.S.A., Inc. Grants and Research Support: Argenx; Grifols; and X4 Pharmaceuticals, Inc. Speakers Bureau: ADMA Biologics, Inc. and Grifols
Dr. Hernandez-Trujillo reports the following financial relationships: Advisory Board: Aimmune Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.; and US WorldMeds. Consultant: Amgen Inc.; CSL; Kaleo, Inc.; National Peanut Board; Pharming; and Takeda Pharmaceuticals U.S.A., Inc. Grants: Immune Deficiency Foundation. Speakers Bureau: CSL Behring and Takeda Pharmaceuticals U.S.A., Inc
Ms. Jacqueline reports no financial relationships to disclose.
The following CME Outfitters peer reviewer and staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-23-011-H01-P
Call us at (877) CME-PROS or (877) 263-7767.